Silence Therapeutics has turned in an H1 pretax loss of £5.5m, from a year-earlier's loss of £4.1m.
"Silence has been fully focused on progressing a high conviction IND/CTA filing to spearhead the platform potential of RNA therapeutics," said CEO Ali Mortazavi in a statement.
"Central to this have been the key senior hires from the biopharma industry in conjunction with rapid progress in the powerful GalNAc liver technology. A proportion of our R&D budget has also been focused on high impact R&D areas such as CRISPR, where we believe that we can license or partner enabling technologies for larger players in the field.
"In addition to our core science, through the licensing of our IP and newly granted patents, we are represented in the clinic in Phase 2 and 3 trials as well as continuing discussions around possible new licences to our own patents with competitors in the field.
"Recent legal advice in regards to our IP has further increased our confidence that this element of our business alone could represent a significant proportion of the current market capitalisation of the Company."
At 9:53am: (LON:SLN) Silence Therapeutics PLC share price was -0.62p at 117.38p